Claims for Patent: 5,844,099

Summary for Patent: 5,844,099

Title:	Cytokine antagonists
Abstract:	Heteromeric proteins comprising a soluble .alpha. specificity determining cytokine receptor component and the extracellular domain of a .beta. receptor component function as cytokine antagonists.
Inventor(s):	Stahl; Neil (Carmel, NY), Economides; Aris (Dobbs Ferry, NY), Yancopoulos; George D. (Yorktown Heights, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	08/563,105
Patent Claims:	1. A purified antagonist of a cytokine comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the cytokine's receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of a signal transducing component of the cytokine's receptor; wherein the cytokine is selected from the group consisting of interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-15, granulocyte macrophage colony stimulating factor, gamma-interferon, and Transforming Growth Factor-Beta, and the antagonist is capable of binding the cytokine to form a nonfunctional complex. 2. The purified antagonist according to claim 1, which further comprises an immunoglobulin derived domain capable of forming a complex between said extracellular domain of said specificity determining component and said extracellular domain of said signal transducing component. 3. The purified antagonist according to claim 2, in which said immunoglobulin domain is the Fc domain of IgG. 4. The purified antagonist according to claim 2, in which said immunoglobulin domain is a heavy chain of IgG. 5. The purified antagonist according to claim 4, in which said heavy chain is C-gamma1 or C-gamma4. 6. The purified antagonist according to claim 2, in which said immunoglobulin domain is a light chain of IgG. 7. The purified antagonist according to claim 6, in which said light chain is the kappa chain of IgG. 8. The purified antagonist according to claim 6, in which said light chain is the lambda chain of IgG. 9. A purified antagonist of interleukin-1 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-1 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-1 receptor; wherein the antagonist is capable of binding interleukin-1 to form a nonfunctional complex. 10. A purified antagonist of interleukin-2 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-2 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-2 receptor; wherein the antagonist is capable of binding interleukin-2 to form a nonfunctional complex. 11. A purified antagonist of interleukin-3 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-3 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-3 receptor; wherein the antagonist is capable of binding interleukin-3 to form a nonfunctional complex. 12. A purified antagonist of interleukin-4 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-4 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-4 receptor; wherein the antagonist is capable of binding interleukin-4 to form a nonfunctional complex. 13. A purified antagonist of interleukin-5 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-5 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-5 receptor; wherein the antagonist is capable of binding interleukin-5 to form a nonfunctional complex. 14. A purified antagonist of interleukin-15 comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the interleukin-15 receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the interleukin-15 receptor; wherein the antagonist is capable of binding interleukin-15 to form a nonfunctional complex. 15. A purified antagonist of granulocyte macrophage colony stimulating factor comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the granulocyte macrophage colony stimulating factor receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the granulocyte macrophage colony stimulating factor receptor; wherein the antagonist is capable of binding granulocyte macrophage colony stimulating factor to form a nonfunctional complex. 16. A purified antagonist of gamma-interferon comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the gamma-interferon receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the gamma-interferon receptor; wherein the antagonist is capable of binding gamma-interferon to form a nonfunctional complex. 17. A purified antagonist of Transforming Growth Factor-Beta comprising: a) the extracellular domain but not the transmembrane and cytoplasmic domains of the specificity determining component of the Transforming Growth Factor-Beta receptor; and b) the extracellular domain but not the transmembrane and cytoplasmic domains of the signal transducing component of the Transforming Growth Factor-Beta receptor; wherein the antagonist is capable of binding Transforming Growth Factor-Beta to form a nonfunctional complex.

Details for Patent 5,844,099

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kiniksa Pharmaceuticals (uk), Ltd.	ARCALYST	rilonacept	For Injection	125249	February 27, 2008		2013-10-20

International Patent Family for US Patent 5,844,099

Country	Patent Number	Estimated Expiration
South Africa	948242
World Intellectual Property Organization (WIPO)	9511303
United States of America	5470952
Portugal	726954
Japan	H09504030
Japan	3961562